** Bachem BANB.S shares fall 7% following the Swiss
biotech supplier's FY results, falling short of market
expectations
** The Swiss company reported an EBITDA margin of 30.2%,
slightly under market expectations of 30.8% according to
Vontobel
** "Bachem released slightly lower FY22 results, which met
neither market expectations nor our lower estimates" Vontobel
notes
** Bachem falls to the bottom of Switzerland's midcaps index
.MDAXI , and are on track for their worst day since last August
(Reporting by Tristan Chabba)
((Tristan.chabba@thomsonreuters.com))